A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

Axel Bex; Laurence Albiges; Michael Staehler; Karim Bensalah; Rachel H. Giles; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A. Kuczyk; Thomas B. Lam; Lorenzo Marconi; Axel S. Merseburger; Sergio Fernández-Pello; Rana Tahbaz; Yasmin Abu-Ghanem; Alessandro Volpe; Börje Ljungberg; Bernard Escudier; Thomas Powles

doi:10.1016/j.eururo.2018.08.029

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

Axel Bex, Laurence Albiges, Michael Staehler, Karim Bensalah, Rachel H. Giles, Saeed Dabestani, Fabian Hofmann, Milan Hora, Markus A. Kuczyk, Thomas B. Lam, Lorenzo Marconi, Axel S. Merseburger, Sergio Fernández-Pello, Rana Tahbaz, Yasmin Abu-Ghanem, Alessandro Volpe, Börje Ljungberg, Bernard Escudier, Thomas Powles

Urologi

Forskningsoutput: Tidskriftsbidrag › Letter › Peer review

Originalspråk	engelska
Sidor (från-till)	849-851
Antal sidor	3
Tidskrift	European Urology
Volym	74
Nummer	6
DOI	https://doi.org/10.1016/j.eururo.2018.08.029
Status	Published - 2018

Ämnesklassifikation (UKÄ)

Cancer och onkologi
Klinisk medicin

FN:s Globala mål

Denna forskningsoutput relaterar till följande Globala mål

Tillgång till dokument

10.1016/j.eururo.2018.08.029

Citera det här

Bex, A., Albiges, L., Staehler, M., Bensalah, K., Giles, R. H., Dabestani, S., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T. B., Marconi, L., Merseburger, A. S., Fernández-Pello, S., Tahbaz, R., Abu-Ghanem, Y., Volpe, A., Ljungberg, B., Escudier, B., & Powles, T. (2018). A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. European Urology, 74(6), 849-851. https://doi.org/10.1016/j.eururo.2018.08.029

Bex, Axel ; Albiges, Laurence ; Staehler, Michael et al. / A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition : The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. I: European Urology. 2018 ; Vol. 74, Nr. 6. s. 849-851.

@article{dc34d3e45be5497aa6fe5d2ea69e6b53,

title = "A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations",

author = "Axel Bex and Laurence Albiges and Michael Staehler and Karim Bensalah and Giles, {Rachel H.} and Saeed Dabestani and Fabian Hofmann and Milan Hora and Kuczyk, {Markus A.} and Lam, {Thomas B.} and Lorenzo Marconi and Merseburger, {Axel S.} and Sergio Fern{\'a}ndez-Pello and Rana Tahbaz and Yasmin Abu-Ghanem and Alessandro Volpe and B{\"o}rje Ljungberg and Bernard Escudier and Thomas Powles",

year = "2018",

doi = "10.1016/j.eururo.2018.08.029",

language = "English",

volume = "74",

pages = "849--851",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "6",

}

Bex, A, Albiges, L, Staehler, M, Bensalah, K, Giles, RH, Dabestani, S, Hofmann, F, Hora, M, Kuczyk, MA, Lam, TB, Marconi, L, Merseburger, AS, Fernández-Pello, S, Tahbaz, R, Abu-Ghanem, Y, Volpe, A, Ljungberg, B, Escudier, B & Powles, T 2018, 'A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations', European Urology, vol. 74, nr. 6, s. 849-851. https://doi.org/10.1016/j.eururo.2018.08.029

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. / Bex, Axel; Albiges, Laurence; Staehler, Michael et al.
I: European Urology, Vol. 74, Nr. 6, 2018, s. 849-851.

Forskningsoutput: Tidskriftsbidrag › Letter › Peer review

TY - JOUR

T1 - A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition

T2 - The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

AU - Bex, Axel

AU - Albiges, Laurence

AU - Staehler, Michael

AU - Bensalah, Karim

AU - Giles, Rachel H.

AU - Dabestani, Saeed

AU - Hofmann, Fabian

AU - Hora, Milan

AU - Kuczyk, Markus A.

AU - Lam, Thomas B.

AU - Marconi, Lorenzo

AU - Merseburger, Axel S.

AU - Fernández-Pello, Sergio

AU - Tahbaz, Rana

AU - Abu-Ghanem, Yasmin

AU - Volpe, Alessandro

AU - Ljungberg, Börje

AU - Escudier, Bernard

AU - Powles, Thomas

PY - 2018

Y1 - 2018

U2 - 10.1016/j.eururo.2018.08.029

DO - 10.1016/j.eururo.2018.08.029

M3 - Letter

C2 - 30201510

AN - SCOPUS:85056208512

SN - 0302-2838

VL - 74

SP - 849

EP - 851

JO - European Urology

JF - European Urology

IS - 6

ER -

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S et al. A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. European Urology. 2018;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029